Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.54 USD
Change Today -0.02 / -0.36%
Volume 363.9K
As of 8:10 PM 05/21/15 All times are local (Market data is delayed by at least 15 minutes).

progenics pharmaceuticals (PGNX) Key Developments

Progenics Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Progenics Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $248,000 against $1,815,000 for the same period a year ago, reflecting RELISTOR royalty income of $0.1 million compared to $0.7 million in the 2014 period, based on net sales reported to the company by its commercialization partner, Valeant Pharmaceuticals International, Inc. The decrease in royalty revenue reflects a short-term wholesaler inventory reduction initiative implemented in the fourth quarter of 2014 by Salix Pharmaceuticals, Inc., which was subsequently acquired by Valeant. In addition, collaboration revenue declined to $0.1 million from $1.0 million in the 2014 period, primarily due to a milestone from Fuji recognized in the first quarter of 2014. Operating loss was $10,266,000 against $9,325,000 for the same period a year ago. Net loss was $10,254,000 or $0.15 per basic and diluted share against $9,313,000 or $0.15 per basic and diluted share for the same period a year ago.

Progenics Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 06, 2015

Progenics Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 06, 2015

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. Announces RELISTOR Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain

April 24, 2015 Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a new indication for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for RELISTOR, to 11 years from the date of approval, citing the fact that RELISTOR offers a major contribution to patient care in comparison to existing therapies. The CHMP is responsible for reviewing medicinal product applications for safety, quality and efficacy. The CHMP's positive opinion on RELISTOR will be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The final decision will be applicable to all 28 European Union member countries plus Iceland and Norway. If approved, it is anticipated that RELISTOR will be immediately available to this newly expanded population of patients in the EU using opioids to control chronic non-cancer pain.

Progenics Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 02:20 PM

Progenics Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 02:20 PM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Mark R. Baker, Chief Executive Officer, Director and Member of Science & Strategy Committee.

Progenics Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Reports Impairment Charges for the Fourth Quarter of 2014

Progenics Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. The company reported Fourth quarter revenue resulted in a loss of $0.6 million, primarily from RELISTOR royalty losses due to Salix's plan to accelerate the reduction of wholesaler inventory levels and substantially cease all sales efforts to wholesalers in the fourth quarter of 2014. This compares to revenues of $3.0 million due to RELISTOR royalty income in the fourth quarter of 2013. Operating loss was $12,954,000 against $8,923,000 a year ago. Net loss before income tax benefit was $12,940,000 against $8,913,000 a year ago. Net loss was $12,179,000 or $0.18 per basic and diluted share against $8,551,000 or $0.14 per basic and diluted share a year ago. For the year, the company reported total revenue of $44,377,000 against $7,862,000 a year ago. Operating income was $3,370,000 against operating loss of $42,980,000 a year ago. Net income before income tax benefit was $3,421,000 against net loss before income tax benefit of $42,934,000 a year ago. Net income was $4,410,000 or $0.06 per basic and diluted share against net loss of $42,572,000 or $0.76 per basic and diluted share a year ago. Full year 2014 revenue was up from the prior year, reflecting an increase in collaboration revenue, primarily resulting from the recognition of milestone from Salix, partially offset by decrease in RELISTOR royalty income, compared to 2013. For the quarter, the company reported intangible impairment charges of $2,100,000.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGNX:US $5.54 USD -0.02

PGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $1.74 USD -0.02
Genocea Biosciences Inc $10.97 USD -0.62
Inovio Pharmaceuticals Inc $8.26 USD +0.05
Peregrine Pharmaceuticals Inc $1.33 USD +0.02
Rigel Pharmaceuticals Inc $3.68 USD -0.20
View Industry Companies
 

Industry Analysis

PGNX

Industry Average

Valuation PGNX Industry Range
Price/Earnings 100.0x
Price/Sales 9.0x
Price/Book 3.4x
Price/Cash Flow 96.8x
TEV/Sales 6.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGENICS PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.